And as to efficacy - two large animal studies show it works :...

And as to efficacy - two large animal studies show it works :

“The initial biological efficacy profile observedfor BB-301 following in vivo testing in the murine model of Oculopharyngeal Muscular Dystrophy,including full correction of the disease phenotype, remains unchanged”

Benitec wants to make improvements to delivery but Axovant don’t want to wait because their other drugs are failing to excite investor sentiment.

This is a win for Benitec for those who can see it.